Message #3 From:
NewsBot Date: July 24, 2006 11:03:00 AM
HBSC News Harry Masuda, CEO of Human BioSystems, to be Interviewed by Market News First Radio (MN1.com)
PALO ALTO, Calif.--(BUSINESS WIRE)--July 24, 2006--Human BioSystems (OTCBB:HBSC) announced today that Harry Masuda, CEO, will be interviewed by Market News First Radio (http://www.mn1.com), today (July 24, 2006) at 3:30 EDT.
In this exclusive interview, Mr. Masuda will enlighten the listening audience on Human BioSystems and their recent milestone achievement in completing their second independent study of their breakthrough technology for the preservation of blood platelets.
Human BioSystems, a developer of preservation platforms for organs and other biomaterials, specializing in the development of proprietary above zero ("HBS-AZ") and below zero ("HBS-BZ") organ and tissue preservation systems and methods for preserving blood platelets, has made tremendous advancements in their research and testing of their proprietary preservation methods over the past year and is now beginning the process to prepare their application to the FDA to obtain a license to begin performing human testing.
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for human studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, issues with the patentability and/or protection of the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
